Les données mises à jour de l‘essai de phase 1 du traitement oral IDHIFA® (enasidenib) montrent des réponses cliniques durables chez les patients atteints d’une leucémie aiguë myéloïde en rechute ou réfractaire avec mutation IDH2

Our Review Board

Our content is carefully reviewed by experienced professionals to ensure accuracy and relevance.

• Qualified Experts: Each article is assessed by specialists with field-specific knowledge.
• Up-to-date Insights: We incorporate the latest research, trends, and standards.
• Commitment to Quality: Reviewers ensure clarity, correctness, and completeness.

Look for the expert-reviewed label to read content you can trust.